000513.SZ logo
SHZ · 000513.SZDrug Manufacturers - Specialty & GenericUpdated Nov 10, 2026

Livzon Pharmaceutical Group Inc. P/E ratio

Current valuation, historical context, and peer comparisons.

Current P/E ratio

17.95×

3.7% belowthe 10-year annual average

Share price31.29
÷
Earnings per share1.7434

Price and EPS in quote currency. Calculation details

Investors are paying 17.95 for every 1 of reported earnings per share.

P/E over time

2016 – 2025
Annual P/ESelected-period average 18.64×
3-year average16.27×3 positive annual observations
5-year average17.18×5 positive annual observations
10-year average18.64×10 positive annual observations
Peer median · TTM20.81×8 peers with positive P/E

Historical P/E ratios

Annual period-end data · 25 observations

000513.SZ annual P/E history, newest first
Period endP/EChange
Dec 31, 202515.18×-10.5%
Dec 31, 202416.96×+1.8%
Dec 31, 202316.67×+4.7%
Dec 31, 202215.92×-24.8%
Dec 31, 202121.16×-4.4%
Dec 31, 202022.13×-8.7%
Dec 31, 201924.24×+53.7%
Dec 31, 201815.78×+91.8%
View all 25 annual observations +
000513.SZ annual P/E history, newest first
Period endP/EChange
Dec 31, 20178.23×-72.7%
Dec 31, 201630.09×-14.8%
Dec 31, 201535.32×+24.5%
Dec 31, 201428.38×+21.5%
Dec 31, 201323.36×-0.3%
Dec 31, 201223.42×+40.7%
Dec 31, 201116.65×-45.7%
Dec 31, 201030.68×+24.0%
Dec 31, 200924.75×-75.8%
Dec 31, 2008102.35×+294.2%
Dec 31, 200725.97×+158.4%
Dec 31, 200610.05×-17.4%
Dec 31, 200512.17×-25.3%
Dec 31, 200416.29×-0.6%
Dec 31, 200316.38×-47.7%
Dec 31, 200231.33×-26.0%
Dec 31, 200142.35×N/M

Change is relative to the preceding observation. N/M values are excluded from averages.

How 000513.SZ compares

Company P/E vs. peer trailing-12-month ratios

P/E comparison with 000513.SZ and provider-selected peers
CompanyP/E ratio
000513.SZ logo
000513.SZ This stockLivzon Pharmaceutical Group Inc.
17.95×
600380.SS logo
600380.SSJoincare Pharmaceutical Group Industry Co.,Ltd.
16.87×
000999.SZ logo
000999.SZChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
13.09×
600664.SS logo
600664.SSHarbin Pharmaceutical Group Co., Ltd.
22.81×
002294.SZ logo
002294.SZShenzhen Salubris Pharmaceuticals Co., Ltd.
47.77×
600196.SS logo
600196.SSShanghai Fosun Pharmaceutical (Group) Co., Ltd.
17.59×
002422.SZ logo
002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A
35.58×
600276.SS logo
600276.SSJiangsu Hengrui Medicine Co., Ltd.
35.96×
000538.SZ logo
000538.SZYunnan Baiyao Group Co.,Ltd
18.80×

Peers are selected by the data provider. Business models and earnings definitions can differ.

Put the numbers in context

What does 000513.SZ’s P/E tell you?

01

Start with its own history

At 17.95×, 000513.SZ is 3.7% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

02

Compare like with like

The median of the 8 positive peer ratios above is 20.81×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.

03

Check what drives earnings

One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.

Keep your research connected

Take 000513.SZ into your spreadsheet

Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.

Explore Wisesheets
Quarterly P/E · latest quarter
=WISE("000513.SZ", "PE Ratio", "LQ")
LQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data

Sources & calculation methodology

Current P/E

Share price 31.29 ÷ EPS 1.7434 = 17.95×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 10, 2026; this is not a real-time trading quote.

History & averages

Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.

Data definitions and limitations

The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.

000513.SZ P/E ratio: common questions

The essentials behind the numbers.

Livzon Pharmaceutical Group Inc.'s current P/E is 17.95× based on the quote data last updated Nov 10, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.